[Iron chelating therapy in adults: How and when ?]

Area of Science:

• Hematology
• Pharmacology
• Toxicology

Background:

• Iron overload leads to free radical toxicity and tissue damage.
• Phlebotomy is the primary treatment for iron overload.
• Iron chelation therapy is crucial when phlebotomy is not feasible, particularly in anemic patients.

Purpose of the Study:

• To review iron overload treatments, focusing on iron chelation therapy.
• To compare different iron chelating agents and their efficacy.
• To outline monitoring guidelines for iron overload using MRI.

Main Methods:

• Literature review of iron overload treatments and chelation therapies.
• Comparison of oral and parenteral iron chelators: desferrioxamine, deferiprone, and deferasirox.
• Discussion of diagnostic and monitoring tools, including MRI for liver and cardiac iron.

Main Results:

• Iron chelation therapy significantly improves life expectancy in conditions like thalassemia major.
• Oral chelators (deferiprone, deferasirox) offer compliance advantages over parenteral desferrioxamine, but have specific limitations.
• MRI T2* < 20ms indicates cardiac iron load, necessitating specific treatment strategies.

Conclusions:

• Iron chelation therapy is vital for managing iron overload in various hematological disorders.
• Choice of iron chelator depends on patient condition, compliance, and specific organ involvement (e.g., myocardium).
• Regular monitoring with MRI is essential for effective management of iron overload and prevention of complications.